Jeffrey S. Ramsay

Davis Polk advised Charles River Laboratories International, Inc. in connection with its Rule 144A/Regulation S offering of $500 million aggregate principal amount of 4.250% senior notes…

Davis Polk advised the lead managers on an SEC-registered offering by TD Bank of (i) $1.15 billion aggregate principal amount of its 1.900% senior notes due 2022 and (ii) $350 million…

Davis Polk advised the underwriters in connection with the offering of $1.25 billion aggregate principal amount of 2.000% bonds due October 2, 2029 issued by the Province of Ontario. The…

Davis Polk advised the underwriters in connection with the SEC-registered offering by BioXcel Therapeutics, Inc. of 2,303,030 shares of its common stock. The common stock is listed on the…

Davis Polk advised the underwriters in connection with the offering of $1.25 billion aggregate principal amount of 1.750% bonds due 2024, issued by the Province of British Columbia. The…

Davis Polk advised the lead managers on an SEC-registered offering by TD Bank of $1.25 billion aggregate principal amount of its floating-rate senior notes due 2021, under its medium-term…

Davis Polk advised the initial purchasers on a Rule 144A/Regulation S offering by YUM! Brands, Inc. of $800 million aggregate principal amount of 4.75% senior notes due 2030. Proceeds from…

Davis Polk advised the dealer managers in connection with a “modified Dutch auction” cash tender offer by Alliance Data Systems Corporation for 5,050,505 of its shares of common stock…

Davis Polk advised the joint book-running managers in connection with the SEC-registered offering by Deciphera Pharmaceuticals, Inc. of 10,810,810 shares of common stock for gross proceeds…

Davis Polk advised Freeport-McMoRan Inc. (“FCX”) in connection with its SEC-registered offering of $1.2 billion of senior notes. The offering consisted of two tranches of senior notes,…